The stock may react positively to strong 2026 guidance and upcoming regulatory catalysts, particularly the July 2026 PDUFA decision. Traders should monitor prescription trends in Q1 2026 to confirm recovery from prior supply disruptions and watch for data readouts from MONARCH (MASH) and BELLA (ovarian cancer) trials later this year.
CORT drugs
CORT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $36.22entry
- T+1 · 9mo ago −1.21%α −0.67% · $35.78
- T+5 · 9mo ago −1.46%α −0.36% · $35.69
- T+20 · 8mo ago +11.73%α +16.97% · $40.47
- T+60 · 6mo ago +63.06%α +56.11% · $59.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corcept Therapeutics reported full-year 2025 revenue of $761.4 million, a 12.8% increase from 2024, driven by strong demand in its Cushing's syndrome business despite supply constraints. However, net income declined 29.4% to $99.7 million due to higher operating expenses. The company issued bullish 2026 revenue guidance of $900–$1,000 million, representing 18–32% growth, and highlighted key upcoming catalysts including a July 2026 PDUFA date for relacorilant in ovarian cancer and data readouts from multiple late-stage trials.
Key Financial Metrics
Key Facts
- 2025 revenue: $761.4 million (up 12.8% YoY from $675.0 million)
- 2025 net income: $99.7 million (down 29.4% YoY from $141.2 million)
- 2025 diluted EPS: $0.82 (down 33.3% YoY from $1.23)
- Full-year 2026 revenue guidance: $900–$1,000 million (18–32% growth)
- Cash and investments: $532.4 million at year-end 2025
- PDUFA date for relacorilant in platinum-resistant ovarian cancer: July 11, 2026
- ROSELLA trial met dual endpoints with 35% reduction in risk of death
- Phase 3 trial of dazucorilant in ALS planned for mid-2026
Financial Impact
Revenue growth of $86.4 million in 2025, but net income down $41.5 million. 2026 guidance implies $138.6–$238.6 million revenue increase.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cushing's syndrome | $761.4M | +12.8% |
Risk Factors
- Declining profitability despite revenue growth
- FDA approval uncertainty for relacorilant in Cushing's syndrome after Complete Response Letter
- Execution risk in transitioning to new specialty pharmacy and scaling operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-011080 |
| Document: cort-20260224.htm | 0001628280-26-011080 |
| Document: 0001628280-26-011080-index-headers.html | 0001628280-26-011080 |
| Document: 0001628280-26-011080-index.html | 0001628280-26-011080 |
| Document: 0001628280-26-011080.txt | 0001628280-26-011080 |
Track record
36 reports on CORT
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +60.95% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers